AI assistant
Sending…
Royalty Pharma plc — Director's Dealing 2025
Nov 7, 2025
30286_dirs_2025-11-07_cce80345-fef6-4391-a848-1005811d7376.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Royalty Pharma plc (RPRX)
CIK: 0001802768
Period of Report: 2025-11-05
Reporting Person: Hite Christopher (EVP & Vice Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | Class A Ordinary Shares | A | 6168 | — | Acquired | 658510 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Ordinary Shares | 70000 | Direct |
Footnotes
F1: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.
More from Royalty Pharma plc
Regulatory Filings
2026
May 28
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Mar 19
Regulatory Filings
2026
Mar 18
Director's Dealing
2026
Mar 4
Director's Dealing
2026
Feb 25
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 13